E.g. "breast cancer" HER2 Smith J

Stenting and medical therapy for atherosclerotic renal-artery stenosis.

(PMID:24245566 PMCID:PMC4815927)
, 
, 
, 
, 
, 
, 
, 
, 
, 
, 
, 
, 
, 
, 
, 
, 
, 
, 
 
Affiliations
  • 1. From the University of Toledo, Toledo, OH (C.J.C.); Rhode Island Hospital (T.P.M., L.D.D.) and Alpert Medical School of Brown University (T.P.M., L.D.D.) - both in Providence; Harvard Clinical Research Institute (D.E.C., J.M.M., R.B.D.), Beth Israel Deaconess Medical Center (D.E.C.), Massachusetts General Hospital (M.R.J.), Brigham and Women's Hospital (E.F.L.), and Boston University School of Public Health (R.B.D.) - all in Boston; University of Michigan, Ann Arbor (K.J.); University of Texas Health Science Center, San Antonio (W.H.); National Heart, Lung and Blood Institute, Bethesda, MD (D.M.R.); Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); University of Virginia, Charlottesville (A.H.M.); University of Minnesota, Minneapolis (M.S.); Weill Cornell Medical Center, New York (M.R.P.); Providence Sacred Heart Medical Center and University of Washington School of Medicine, Spokane (K.R.T.); Marshall University, Huntington, WV (J.I.S.); and Holy Name Medical Center, Teaneck NJ (J.H.R.).
  • 2. No matching affiliation detected.
Close affiliations

The New England Journal of Medicine [18 Nov 2013, 370(1):13-22]
Type: research-article, Multicenter Study, Randomized Controlled Trial, Journal Article, Research Support, N.I.H., Extramural
DOI: 10.1056/NEJMoa1310753 The Digital Object Identifier (DOI) System enables identification of digital entities

A comment on this article appears in "What is the optimal treatment for patients with atherosclerotic renal artery stenosis?" Am J Kidney Dis. 2014 Aug;64(2):174-7.

A comment on this article appears in "Stenting for renal-artery stenosis." N Engl J Med. 2014 May 8;370(19):1853-4.

A comment on this article appears in "Stenting for renal-artery stenosis." N Engl J Med. 2014 May 8;370(19):1853.

A comment on this article appears in "Stenting for renal-artery stenosis." N Engl J Med. 2014 May 8;370(19):1854.

A comment on this article appears in "Stenting for renal-artery stenosis." N Engl J Med. 2014 May 8;370(19):1852-3.

A comment on this article appears in "Stenting for renal-artery stenosis." N Engl J Med. 2014 May 8;370(19):1852.

A comment on this article appears in "Stenting for renal-artery stenosis." N Engl J Med. 2014 May 8;370(19):1854-5.

A comment on this article appears in "Do kidneys need blood?" Eur J Vasc Endovasc Surg. 2014 May;47(5):459-60.

A comment on this article appears in "Treatment of atherosclerotic renovascular disease." N Engl J Med. 2014 Jan 2;370(1):78-9.

A comment on this article appears in "Is time of renal hypoperfusion an important variable in determining response to renal artery revascularization?" JACC Cardiovasc Interv. 2014 Jan;7(1):110.

Show all items

Abstract

Atherosclerotic renal-artery stenosis is a common problem in the elderly. Despite two randomized trials that did not show a benefit of renal-artery stenting with respect to kidney function, the usefulness of stenting for the prevention of major adverse renal and cardiovascular events is uncertain.We randomly assigned 947 participants who had atherosclerotic renal-artery stenosis and either systolic hypertension while taking two or more antihypertensive drugs or chronic kidney disease to medical therapy plus renal-artery stenting or medical therapy alone. Participants were followed for the occurrence of adverse cardiovascular and renal events (a composite end point of death from cardiovascular or renal causes, myocardial infarction, stroke, hospitalization for congestive heart failure, progressive renal insufficiency, or the need for renal-replacement therapy).Over a median follow-up period of 43 months (interquartile range, 31 to 55), the rate of the primary composite end point did not differ significantly between participants who underwent stenting in addition to receiving medical therapy and those who received medical therapy alone (35.1% and 35.8%, respectively; hazard ratio with stenting, 0.94; 95% confidence interval [CI], 0.76 to 1.17; P=0.58). There were also no significant differences between the treatment groups in the rates of the individual components of the primary end point or in all-cause mortality. During follow-up, there was a consistent modest difference in systolic blood pressure favoring the stent group (-2.3 mm Hg; 95% CI, -4.4 to -0.2; P=0.03).Renal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease. (Funded by the National Heart, Lung and Blood Institute and others; ClinicalTrials.gov number, NCT00081731.).
Loading...

Read Article at publisher's site Exit

Menu

Formats
Abstract
Full Text
PDF

Cited by view all